Scottish Development International
Scottish Development International offers free and confidential support to foreign companies who would like to identify commercial, clinical or academic partners in Scotland. SDI can also offer a wide range of investor support services for companies expanding in Europe.
The Scottish Life Sciences sector consists of over 650 organisations employing over 32,500 people with particular strengths in cell and gene therapy, pharmaceutical services, digital health and clinical translational medicine.
Scotland has a strong cluster of expert, innovative and ambitious companies delivering outsourcing solutions for biopharmaceutical companies globally. This includes both multi-national and niche CROs, innovative drug delivery and formulation specialists and manufacturing services that span drug development.
Scotland is also in the top three centres for drug discovery and development in the UK and has a streamlined process for establishing clinical trials with fast approval times.
Sekisui has been a leader in the manufacturing of high quality enzymes and specialist biochemicals to the global healthcare market for over 40 years. We have worked with many global partners to supply high quality materials for a variety of applications, including enzymes for bio-therapeutic manufacture, pharmaceutical production, clinical chemistry reagents, point-of-care / biosensor devices. We offer a process development, fermentation and purification competency.
Sekisui is seeking to connect with Bio-Pharma Companies or Developers requiring contract manufacturing services, including process development or scale up where required. Our expertise resides in the manufacture of enzymes, proteins, or antibodies based on microbial fermentation.
Further, we are seeking partners in contract manufacturing and with contract research organizations in the area of enzyme / protein development and manufacture for the Bio-Pharma sector.
Stratophase is a biotech services company that is revolutionising the timelines to clinic and commercialisation for biologics. We do this by rapidly optimising biomanufacturing processes using our Ranger technology to dynamically control the bioreactor environment in real time. Our Ranger® service and technology provide an innovative approach to bioreactor culture optimisation based on in-line, continuous assessment of the metabolic activity of the cell culture combined with a well established Probing Control Strategy.
Ranger uses Adaptive Bioprocess Control to find and maintain optimal conditions that may vary over time during the manufacturing process. To do this we use our patented technology, combined with Stratophase’s extensive application expertise gained from over 300 customer processes and collaborations with industry-leading biopharma innovators, including GSK and Pfizer.
Ranger's adaptive and dynamic feed on demand capability, based on the metabolic demands of the bioreactor culture, is used to rapidly optimise the bioreactor process with either single or multi-component feed strategies, as demonstrated with our recently announced collaboration with Merck. The adaptive and scale-independent capability of Ranger delivers significant advantages to batch, fed batch and continuous manufacturing strategies, as well as autologous and allogeneic cell therapy processes.